Abstract library

47 results for "Brais".
#2085 Alpha-Fetoprotein in Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: A Single Centre Study
Introduction: Several attempts to determine prognostic factors in neuroendocrine setting have been made, with inconsistent results until now. Alpha-fetoprotein (AFP) has previously been reported as being elevated in some neuroendocrine neoplasms (NENs), even if the actual clinical implications of this marker in this setting are unclear.
Conference: 15th Annual ENETS conference (2018)
Category: Biomarkers
Presenting Author: MD Roberta Elisa Rossi
#294 Chromogranin B is a Prognostic Marker in NETs
Introduction: Chromogranin B (CgB) co-localizes with Chromogranin A (CgA) in the secretory granules of neuroendocrine cells. Previous studies have investigated CgA, but not CgB, as a prognostic marker in NETs.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Mr Paul R Bech
#728 NETworking-The First Three Years of the World NET Cancer Awareness Day Alliance
Introduction: Neuroendocrine tumors have an incidence of 3-5/100,000 per year, however, many patients are diagonosed late in their clinical course resulting in poor outcomes and early death. Raising awareness of the myriad presenting symptoms with resultant early diagnosis is a priority health care initiative for this disease. In 2010, the World NET Cancer Day Awareness (WNCAD) Alliance was formed with the primary mission to raise awareness of neuroendocrine tumors and promote November 10 as World NET Cancer Awareness Day
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Dr John C Leyden
Authors: Leyden J, Sissons M, Goldstein G, ...
#823 Association Between Tumor Expression of VEGFA, VEGFR1 (FLT1), VEGFR2 (KDR), and Clinical Outcomes in Neuroendocrine Tumors
Introduction: Clinical studies have suggested efficacy of VEGF pathway inhibitors in the treatment of advanced neuroendocrine tumors (NETs).
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Dr. Zhirong Qian
#993 Analysis of Somatostatin Receptors Expression in Neuroendocrine Tumors
Introduction: Clinical studies have suggested anti-tumor efficacy of somatostatin analog (SSA) in the treatment of neuroendocrine tumors (NETs).
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Dr Tingting Li
Authors: Li T, Qian Z, Ter-Minassian M, Chan J A, ...
Keywords: SSTR2, SSA, NET, OS, PFS
#1810 FOXM1 Is Strongly Associated with Cell Proliferation and Is Not Influenced by Metabolic Syndrome in GEP-NETS
Introduction: Gastro-entero-pancreatic neuroendocrine tumors(GEP-NETs) and metabolic syndrome(MS) are both increasing exponentially. MS has been associated with several non NET cancers.
Conference: 14th Annual ENETS conference (2017)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Dr. Ana Paula Santos
#30 Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia
Introduction: Normal adult lungs contain scattered pulmonary neuroendocrine cells (PNEC). Reactive PNEC hyperplasia is commonly observed in persons who live at high altitude, in cigarette smokers, and in numerous lung diseases. Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH) is a rare entity in which PNEC hyperplasia appears without predisposing conditions. According to the 1999 WHO lung tumor classification, DIPNECH is thought to be primarily a neuroendocrine proliferative process, which can be associated with carcinoid tumors and with a clinical picture of constrictive obliterative bronchiolitis. To date, available data regarding the treatment and the prognosis of this rare condition is limited.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Simona Grozinsky-Glasberg
#66 Adrenocortical cancer: a therapeutic approach with everolimus (RAD001)
Introduction: Adrenocortical cancer (ACC) is a rare disease with very poor outcome. ACC responds poorly to standard chemotherapy. Mitotane, used as adjuvant therapy to surgery, prolongs recurrence-free survival, but the response is limited to 23% of patients and resistance occurs in the majority of patients (1). There is no curative therapy for ACC. Pre-clinical studies have shown involvement of both IGF-2/IGF-1R and Akt/mTOR pathways in ACC, and IGF-1R and mTOR inhibitors inhibited cell proliferation of human adrenocortical carcinoma cell lines in vitro (2,3,4).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Maria Gueorguiev
#83 Surgical treatment of duodenopancreatic neuroendocrine tumors (pNETs) in patients with multiple endocrine neoplasia type 1 (MEN 1): a Dutch consensus statement
Introduction: Duodenopancreatic neuroendocrine tumors (pNETs) in multiple endocrine neoplasia type 1 (MEN 1) are the most important cause of MEN 1-related death. Surgery is the only curative treatment, but controversy exists on the optimal strategy. Recent guidelines on pNETs have limited recommendations specific for MEN 1. Therefore, a Dutch multidisciplinary consensus meeting was organized.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD Carolina RC Pieterman
#124 Management and outcomes of malignant paragangliomas and phaeochromocytomas
Introduction: Chromaffin-cell tumors include phaeochromocytomas and paragangliomas, represent a rare group of neuroendocrine tumors and are located in adrenal medulla or extra-adrenal sites, respectively. Ten percent of phaeochromocytomas and 15-35% of paragangliomas are malignant.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: DR Christos Toumpanakis
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.